What should a Dermani Medspa franchisee do to independently evaluate the franchise opportunity?

According to Dermani Medspa's 2025 Franchise Disclosure Document, prospective franchisees are strongly encouraged to contact and speak with existing franchisees as part of their review and due diligence process. This outreach allows potential franchisees to inquire about the current franchisees' experiences and operational insights.

Furthermore, the FDD emphasizes the importance of reviewing Item 19, which contains historical financial data from certain franchised and affiliate-owned Dermani Medspa locations. However, it is critical to understand that this data is not a guarantee of future results. The FDD advises prospective franchisees to consult with a lawyer, accountant, or other advisor to review Item 19 and fully understand its implications. The document also highlights that a franchisee's results as a start-up business are likely to differ from those of existing Dermani Medspa locations.

In addition to franchisee interviews and financial reviews, Dermani Medspa requires franchisees to acknowledge that their business may be impacted by risks outside of their control, such as economic, political, or social disruptions like the COVID-19 pandemic. These disruptions can lead to reduced customer demand and operational challenges. The FDD also includes a Franchisee Compliance Certification to ensure that prospective franchisees understand the risks of owning their own business and that Dermani Medspa has provided all legally required information. This certification process confirms that no unauthorized promises or statements have been made to the franchisee.

Finally, the FDD provides a list of exhibits, including a list of current and former Dermani Medspa franchisees (Exhibits E and F), which can be valuable resources for gathering information and conducting thorough due diligence. The FDD also includes contact information for state agencies (Exhibit C) to report any violations of federal and state law, such as the failure to deliver the disclosure document on time or if it contains false or misleading statements.